| Date |
Title |
|
| 10 November 2026 |
Results of Meeting |
|
| 10 November 2026 |
CEO Presentation to 2026 Annual General Meeting |
|
| 10 November 2026 |
Mesoblast Chair Message to 2026 AGM |
|
| 10 November 2026 |
Expands Management to Drive Blockbuster Potential of Rex-L |
|
| 10 November 2026 |
Final Director's Interest Notice |
|
| 10 November 2026 |
Final Director's Interest Notice |
|
| 05 November 2026 |
Use of Ryoncil Highlighted in Key Opinion Leader Webinar |
|
| 02 November 2026 |
Final Director's Interest Notice |
|
| 02 November 2026 |
Mesoblast Board Changes |
|
| 29 October 2026 |
Quarterly Activities/Appendix 4C Cash Flow Report |
|
| 27 October 2026 |
Becoming a substantial holder |
|
| 26 October 2026 |
Ceasing to be a substantial holder |
|
| 22 October 2026 |
Becoming a substantial holder |
|
| 16 October 2026 |
MSB Reports Increased Revenue and Improved Operating Spend |
|
| 14 October 2026 |
Notification of cessation of securities - MSB |
|
| 14 October 2026 |
Notification regarding unquoted securities - MSB |
|
| 14 October 2026 |
Application for quotation of securities - MSB |
|
| 12 October 2026 |
Annual Report to Shareholders |
|
| 12 October 2026 |
Notice of Annual General Meeting and Proxy Form |
|
| 12 October 2026 |
Appendix 4G and Corporate Governance Statement |
|
| 01 October 2026 |
Ceasing to be a substantial holder |
|
| 30 September 2026 |
Becoming a substantial holder |
|
| 24 September 2026 |
FDA Approves New Potency Assay for Commercial Ryoncil |
|
| 23 September 2026 |
Ceasing to be a substantial holder |
|
| 27 August 2026 |
MSB Annual Financial Results and Operational Update |
|
| 27 August 2026 |
Annual Financial Results Presentation |
|
| 27 August 2026 |
Preliminary Final Report including Appendix 4E |
|
| 24 August 2026 |
Appendix 3Y - Philip Krause |
|
| 24 August 2026 |
Notification regarding unquoted securities - MSB |
|
| 24 August 2026 |
Mesoblast 2026 Full Year Financial Results Webcast |
|
| 17 August 2026 |
Major Milestone Treatment Completed in P3 Trial for CLBP |
|
| 13 August 2026 |
Becoming a substantial holder |
|
| 07 August 2026 |
Ceasing to be a substantial holder |
|
| 05 August 2026 |
Becoming a substantial holder |
|
| 03 August 2026 |
Ceasing to be a substantial holder |
|
| 31 July 2026 |
Becoming a substantial holder |
|
| 30 July 2026 |
Quarterly Activities/Appendix 4C Cash Flow Report |
|
| 24 July 2026 |
Ceasing to be a substantial holder |
|
| 22 July 2026 |
Ceasing to be a substantial holder |
|
| 21 July 2026 |
Mesoblast CEO Makes Investment to Increase Share Ownership |
|
| 21 July 2026 |
Appendix 3Y - Silviu Itescu |
|
| 21 July 2026 |
Notification regarding unquoted securities - MSB |
|
| 21 July 2026 |
Application for quotation of securities - MSB |
|
| 14 July 2026 |
Notification of cessation of securities - MSB |
|
| 14 July 2026 |
Notification regarding unquoted securities - MSB |
|
| 14 July 2026 |
Application for quotation of securities - MSB |
|
| 14 July 2026 |
Notification regarding unquoted securities - MSB |
|
| 14 July 2026 |
Appendix 3Y - Silviu Itescu |
|
| 14 July 2026 |
Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients |
|
| 10 July 2026 |
Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year |
|
| 01 July 2026 |
Receives FDA BLA Filing Number and Requests Modular Review |
|
| 30 June 2026 |
Becoming a substantial holder |
|
| 29 June 2026 |
Ceasing to be a substantial holder |
|
| 25 June 2026 |
Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility |
|
| 16 June 2026 |
Becoming a substantial holder |
|
| 12 June 2026 |
Ceasing to be a substantial holder |
|
| 02 June 2026 |
ASX CEO Connect Presentation |
|
| 30 April 2026 |
Quarterly Activities/Appendix 4C Cash Flow Report |
|
| 29 April 2026 |
Patient Recruitment Target Achieved in CLBP Pivotal Trial |
|
| 16 April 2026 |
Appendix 3Y for Gregory George |
|
| 16 April 2026 |
Notification of cessation of securities - MSB |
|
| 16 April 2026 |
Notification regarding unquoted securities - MSB |
|
| 16 April 2026 |
Application for quotation of securities - MSB |
|
| 16 April 2026 |
Notification regarding unquoted securities - MSB |
|
| 15 April 2026 |
Acquires CAR Platform for Precision-Enhanced Cell Products |
|
| 08 April 2026 |
Mesoblast R&D Day Presentation |
|
| 08 April 2026 |
Mesoblast R&D Day Features Commercial & Blockbuster Programs |
|
| 08 April 2026 |
Application for quotation of securities - MSB |
|
| 08 April 2026 |
Cleansing Notice |
|
| 07 April 2026 |
Proposed issue of securities - MSB |
|
| 07 April 2026 |
Ryoncil Net Revenue for the Quarter Increases to US$30.3M |
|
| 20 March 2026 |
Appendix 3Ys - S Itescu, E Rose, G George and L Cobley |
|
| 20 March 2026 |
Notification regarding unquoted securities - MSB |
|
| 18 March 2026 |
Mesoblast to Host R&D Day on April 8, 2026 |
|
| 12 March 2026 |
Replacement Appendix 3Y for Gregory George |
|
| 12 March 2026 |
Appointment of Clinical Development and Medical Affairs Head |
|
| 10 March 2026 |
Becoming a substantial holder |
|
| 10 March 2026 |
Appendix 3Y for Gregory George |
|
| 09 March 2026 |
Change in substantial holding |
|
| 27 February 2026 |
Ryoncil Profits Underpinning Substantial Growth Pipeline |
|
| 27 February 2026 |
Corporate Presentation and Half Year Financial Results |
|
| 27 February 2026 |
Half Year Report and Accounts (including Appendix 4D) |
|
| 20 February 2026 |
Mesoblast 2026 Half Year Financial Results Webcast |
|
| 12 February 2026 |
High Survival Rates with Ryoncil in SR-aGvHD EIND Program |
|
| 09 February 2026 |
Becoming a substantial holder |
|
| 29 January 2026 |
Quarterly Activities/Appendix 4C Cash Flow Report |
|
| 27 January 2026 |
Real World Experience with Ryoncil Shows 84% Early Survival |
|
| 27 January 2026 |
Ceasing to be a substantial holder |
|
| 27 January 2026 |
Becoming a substantial holder |
|
| 19 January 2026 |
FDA Confirms Path to Approval for CLBP |
|
| 15 January 2026 |
Notification of cessation of securities - MSB |
|
| 15 January 2026 |
Notification regarding unquoted securities - MSB |
|
| 13 January 2026 |
Notification regarding unquoted securities - MSB |
|
| 13 January 2026 |
Application for quotation of securities - MSB |
|
| 13 January 2026 |
Appendix 3Y for Eric Rose |
|
| 12 January 2026 |
Appendix 3Y for Lyn Cobley |
|
| 09 January 2026 |
Ryoncil Sales for the Quarter Increase 60% to US$35.1M |
|
| 06 January 2026 |
Appendix 3Y for Gregory George |
|
| 06 January 2026 |
Notification of cessation of securities - MSB |
|
| 02 January 2026 |
Mesoblast Announces Changes to Board of Director Roles |
|
